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Chapter I 
Introduction 
1.1 Problem Statement 
Breast Cancer (BCA) is one of the most prevalent cancers affecting women.  
Postmenopausal women have an increased risk for developing breast cancer.  
Approximately 232,670 women living in the United States will be diagnosed with breast 
cancer in 2014.1  Fortunately there is a 90% 5-year survival rate for women diagnosed 
with breast cancer.1   In 2010, aromatase inhibitors (AI), anastrozole, letrozole, and 
exemestane were recommended to be included in the treatment of postmenopausal 
women with hormone receptor positive (HR+) breast cancer.2  Although studies showed 
that AI’s yield a higher survival rate than tamoxifen, and decrease the recurrence rate of 
the cancer, this class of drugs severely deplete the body of estrogen causing a greater 
than 10% side effect of osteoporosis and a 1-10% risk of bone fracture.3   
To date the most common metabolic disorder in postmenopausal women is 
osteoporosis.4  Postmenopausal osteoporosis is brought on by an inadequate amount of 
estrogen along with other risk factors associated with bone loss.4  Estrogen deficiency is 
a dominant causative factor in postmenopausal osteoporosis.5 Other risks for 
postmenopausal osteoporosis include lifestyle practices and nutrition.4  Along with 
osteoporosis, postmenopausal women experience changes in their mouths.  
 Periodontitis is an inflammatory disease characterized by the loss of alveolar bone 
and clinical attachment loss of the soft tissues.6  Although plaque is the primary 
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pathogen that initiates the inflammatory process, the progression of the disease is 
dependent on the role of systemic factors and the host response to bacterial 
mechanisms.7,8   Osteoporotic changes caused by estrogen depletion may be a provoking 
component in periodontal disease. 8   
The depletion of estrogen in postmenopausal women plays a role in skeletal and 
alveolar bone loss.9  Since the oral structures of mice are similar to humans, experimental 
models have been conducted to study the effects of estrogen on periodontal disease. 7  
Skeletal responses of ovariectomy-induced osteopenia in mice parallel those of post-
menopausal women.7  A 2012 experimental study conducted by Kobayashi, et al. 
concluded that the ovariectomy of mice significantly increased alveolar bone loss.   The 
study suggests that osteoporosis due to estrogen depletion, increases alveolar bone 
loss.10   
Studies have shown a relationship between systemic and alveolar bone loss of the 
mandible, resulting in tooth loss.4   Makker et al. concluded tooth loss in postmenopausal 
women may be an indicator of the onset of systemic osteoporosis.4   
Post-menopausal women showed an association between mandibular bone 
mineral density and the bone mineral density of hip, neck, spine, hormones, and markers 
of bone resorption.4 The analysis concluded a positive correlation between menopause, 
number of teeth present and mandibular bone mineral density.4  Research has shown that 
low skeletal bone mineral density is correlated to alveolar bone loss and clinical 
attachment level loss placing postmenopausal women with osteoporosis at a greater risk 
for periodontal disease.6,11  
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Serum biochemical markers can be used to measure the rate of bone resorption 
and bone formation.  The biomarker osteocalcin is a noncollagenous calcium binding 
protein synthesized mainly by osteoblasts.12  Osteocalcin is present in gingival crevicular 
fluid (GCF) and reflects alveolar bone loss.12  Payne et al. examined the relationship 
between serum biomarkers and bone mineral density in post-menopausal women with 
periodontitis and systemic osteopenia.13   The study showed a positive relationship 
between serum bone biomarkers and alveolar bone loss.13 More importantly, this study 
showed osteocalcin as a sensitive biomarker for alveolar bone loss.13 
Due to the advancements in cancer medicine such as early detection and 
treatment, more and more women are surviving BCA.14  AI’s have become the gold 
standard of treatment for post-menopausal women with BCA.15  Given the relationship 
between estrogen depletion, osteoporosis, and periodontitis, we are seeking to see which 
effects AI’s have on alveolar bone loss.  
 
1.2 Goal Statement 
The goal of this investigation is to determine changes in the periodontium 
through the use of clinical parameters, salivary bone biomarkers, and the supplemental 
use of bisphosphonates, vitamin D, and calcium within postmenopausal women on AI. 
 
1.3 Specific Aims 
Specific Aim 1: To examine the changes in the periodontium as measured 
through the clinical periodontal parameters of clinical attachment levels, probing 
depths, bleeding on probing, and linear radiographic measurements in 
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postmenopausal breast cancer survivors on adjuvant aromatase inhibitor therapy 
as compared to those postmenopausal women not on adjuvant aromatase inhibitor 
therapy. Hypothesis: Postmenopausal breast cancer survivors who are on adjuvant 
aromatase inhibitors will exhibit an increase in clinical attachment levels, probing depths, 
bleeding on probing, and a radiographic decrease in bone height as compared to those 
postmenopausal women who are not receiving adjuvant aromatase inhibitor treatment. 
 Specific Aim 2: To determine if postmenopausal breast cancer survivors 
on adjuvant aromatase inhibitors exhibit an increase in alveolar bone loss as 
measured through the salivary biomarker osteocalcin as compared to 
postmenopausal women not on adjuvant aromatase inhibitors. Hypothesis: 
Postmenopausal breast cancer survivors on adjuvant aromatase inhibitors will exhibit a 
higher level of osteocalcin as compared to those postmenopausal women not on adjuvant 
aromatase inhibitors.  
 Specific Aim 3: To determine whether patient demographics and the use of 
bisphosphonates, vitamin D, and calcium have a differential impact on alveolar 
bone loss among postmenopausal breast cancer survivors on adjuvant aromatase 
inhibitors and postmenopausal women not on aromatase inhibitors.  Hypothesis: 
When controlling for demographics, we expect to see a difference in the effects of 
supplemental bisphosphonate, vitamin D, and calcium use between postmenopausal 
breast cancer survivors on aromatase inhibitors and postmenopausal women not on 
aromatase inhibitors.  
 
1.4 Significance: 
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 AIs are widely used to treat breast cancer in postmenopausal women.  These 
drugs profoundly deplete circulating estrogens which in turn may be associated with a 
loss of bone mineral density and an increased risk for osteoporosis and fracture.  These 
conditions are associated with an increased risk for periodontal disease.   At present, 
little is known about the oral side effects of AI.  This is the first study to assess the 
impact of AI on the periodontium.  It will aid in the understanding of oral care prior to 
starting aromatase inhibitor therapy by dental and medical professionals.  The results of 
this study may have an impact on reimbursement policies for dental treatment prior to 
as well as during AI treatment. 
 
1.5 Thesis Overview 
Chapter II, the Review of the Literature, begins with an overview of the 
prevalence of breast cancer in the United States and adjuvant endocrine therapy. This 
is followed by a review of estrogen deficiency and how periodontal disease and 
osteoporosis are linked.  Chapter II concludes with a review of salivary biomarkers and 
whole saliva sampling. Chapter III presents the materials and methods for the overall 
study and discusses the materials and methods of this analysis.  The author presents 
the results in chapter IV, and provides the reader with a comprehensive discussion and 
conclusion in Chapters V and VI. 
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Chapter II 
Review of the Literature 
2.1 Prevalence of Breast Cancer in the United States 
BCA is the most common cancer effecting women and the second leading cause 
of cancer death in women.1  The American Cancer Society estimates that 232,000 women 
living in the United States will annually be diagnosed with breast cancer.1   Although 
incidence of breast cancer is high, the prevalence of death is low.  There is a 90% 5-year 
survival rate for women diagnosed with breast cancer. The etiology of BCA is unknown, 
but established risk factors for breast cancer include family history of breast cancer, 
obesity, an increase in age, dense breast tissue, alcohol consumption, and exogenous 
hormones.16  
 
2.2 Adjuvant Endocrine Therapy 
The main hormone involved in the development and growth of BCA tumors is 
estrogen.17,18  Data have shown that adjuvant endocrine therapy is an effective treatment 
against tumor recurrence among women with HR+ breast cancer.19,20  Anti-estrogen 
therapy is part of adjuvant endocrine care. It reduces recurrence of breast cancer and 
increases patient survival.  Selective estrogen receptive modulators (SERM) such as 
tamoxifen, suppress the growth of hormone receptor positive breast tumors by binding 
the estrogen receptor.18 In contrast, AIs impede the enzyme responsible for the synthesis 
of estrogens from androgenic substrates, causing a distinct suppression of 
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plasma estrogen levels in postmenopausal women.18 Tamoxifen has previously been 
regarded as the gold standard of breast cancer treatment.  AI’s are now recommended 
to be a component of adjuvant endocrine therapy of postmenopausal women with early 
stage HR+ BCA because they further reduce the risk of disease recurrence.17  
Data generated through Phase III randomized controlled clinical trials of 
postmenopausal women with hormone receptor positive breast cancer demonstrate that 
in comparison to tamoxifen alone, the use of an AI as a primary therapy or in sequential 
therapy with tamoxifen improves the length of disease free survival.2 Hence, the AIs are 
a commonly prescribed medication for this population.  AIs prevent conversion of 
androgens to estrogens and do not block ovarian estrogen production, t they are not 
indicated for premenopausal women.18  In postmenopausal women, AIs cause relatively 
rapid decreases in circulating estrogen.18  The toxicities of the AIs include the risk of 
accelerating bone loss and the development of osteoporosis and fractures, as well as a 
musculoskeletal syndrome characterized by bone and joint symptoms of pain and 
stiffness. The etiology and management of this musculoskeletal syndrome remains 
undefined and is undergoing investigation.2  The estrogen deprivation associated with the 
aromatase inhibitors conceivably could affect the oral health of patients on these 
medications.  There is currently limited research on the relationship of AIs and how the 
depletion of estrogen may impact the patient’s oral health. 
 
2.3 Estrogen Deficiency 
Menopause 
Estrogens are steroid compounds produced primarily by the ovaries that are 
important for normal development and functioning of female sexual development as well 
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as playing a crucial role in the skeletal growth and bone homeostasis of women. After the 
cessation of menstrual cycles and the onset of menopause, the primary source of 
circulating estrogen is derived from the conversion of androgens to estrogen in peripheral 
tissues.23  Secondary estrogen sources are produced in small amounts in the liver, 
adrenal glands, fat cells and the breasts.23 This secondary source of estrogen production 
is important for postmenopausal women but the estrogen produced is not at the same 
high levels as in a premenopausal woman.  This lower level of circulating estrogen in 
menopause is associated a higher rate of bone resorption which may exceed that of bone 
deposition, leading to a net loss of bone mass and the risk of osteoporosis.  
In addition to the changes to bone metabolism, menopausal symptoms may be 
present and include hot flashes, irritability, and vaginal atrophy.23 In women with a history 
of breast cancer, use of exogenous estrogens to treat these symptoms is generally 
considered contra-indicated.   
 
Osteoporosis 
  A common metabolic disorder in postmenopausal women is osteoporosis.4  
Osteoporosis is a systemic skeletal condition characterized by low bone mass and the 
deterioration of bone microstructure  which leads to loss of bones strength  and hence an 
increased susceptibility to fractures.4 Approximately 40 percent of women over the age of 
50 will experience a bone fracture related to postmenopausal osteoporosis during their 
lifetime.5 Estrogen deficiency is a dominant risk factor for osteoporosis in postmenopausal 
women causing increased skeletal resorption and relatively decreased bone formation.5 
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 In a low estrogenic state, osteoclasts may resorb bone at a rate that is uncoupled 
from sufficient bone formation by osteoblasts.24 Bone loss ensues and ultimately, with the 
loss of bone mass, the individual becomes at increased risk for bone fractures in the 
bones of the hip, wrist and spine.24 
A review by Weitzmann et al. discusses how  postmenopausal osteoporosis 
should be viewed as a product of an inflammatory disease bearing similarities of an 
organ-limited autoimmune disorder, initiated by estrogen deficiency, and brought on by 
chronic mild decreases in T cell tolerance.25  When estrogen deficiency provokes bone 
loss, an intricate interaction of hormones and cytokines converge to disrupt the process 
of bone remodeling.25  Estrogen deficiency leads to an overall increase in interleukin 
seven (IL-7) production in target organs such as bone, thymus, and spleen, in part 
through decreases in transforming growth factor betta (TGF-β) and increased insulin 
growth factor one (IGF-1) production initiating T cell activation.25   The activated T cells 
release interferon gamma (IFN-γ), which increases antigen presentation by dendritic 
cells and macrophages  by upregulating major histocompatibility complex class II 
expression through the transcription factor class II major histocompatibility complex 
transactivator (CIITA).25  
T cell activation and osteoclastogenesis is magnified by estrogen deficiency 
through down regulation of antioxidant pathways, which ultimately leads to an  
increase in Reactive Oxygen Species (ROS).25  This stimulates antigen presentation and 
the production of tumor necrosis factor (TNF) by mature osteoclasts. Antigen 
presentation is distinctly enriched by the combined effect of IFN-γ and ROS, intensifying  
T cell activation and promoting release of the osteoclastogenic factors receptor activator 
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nuclear factor kappa B ligand (RANKL) and TNF.25  Through the interleukin-one (IL-1) 
upregulation, stromal cell  and osteoblast  RANKL and macrophage colony stimulating 
factor production are further stimulated by TNF forcing osteoclast  formation.25  Direct 
repressive effects of osteoblasts cause TNF and IL-7 to further intensify bone loss by 
diminishing bone formation.25   
Increasing evidence supports the association between osteoporosis and 
periodontal disease.16  For every 1% per year decrease in whole-body bone mineral 
density, there is a more than four times increased risk of tooth loss in postmenopausal 
women.26  These and similar statistics have caused the American Academy of 
Periodontology to consider osteoporosis as a risk factor for periodontal disease.26 
  
2.4 Periodontal Disease 
 Periodontitis is a destructive inflammatory disease characterized by the loss of 
alveolar bone and clinical attachment loss of the soft tissues.6,24 The precursor to 
periodontal disease is gingivitis.  Gingivitis occurs when harmful bacteria accumulate in 
mass and thickness to form a film called plaque. When plaque adheres and remains on 
the tooth surface, especially at the gum line, the gingiva becomes inflamed and easily 
bleeds especially when brushing. At this point, any damage done is limited to the gingival 
tissues and is reversible through improved oral hygiene.26 Although plaque is the primary 
factor that initiates the inflammatory process, the progression of periodontal disease is 
dependent on the role of systemic factors and the host response to bacterial 
mechanisms.7,8  Periodontitis occurs when the inflammatory process is irreversible.  In 
periodontitis, there is a turnover of alveolar bone with an increase of bone resorption and 
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decrease of bone growth resulting in alveolar bone loss, increase in probing depths, and 
clinical attachment loss27  Symptoms such as tooth mobility, tooth loss, and abscesses 
appear late in the disease process. 
 
2.5 Osteoporosis and Periodontitis 
Osteoporotic changes have been seen in the oral cavity as a loss of alveolar bone, 
causing it to be a provoking component in periodontal disease.8  The relationship between 
periodontal disease and osteoporosis was first addressed in 1990 by  Kribbs et al.28,29  
They compared the mandibular bone mass of  85 osteoporotic women and 27 women 
without osteoporosis.  Kribbs et al. reported a lower mandibular bone mass and density 
in the osteoporotic group, however no differences in clinical periodontal measurements 
were found between the two groups [Odds ratio (OR): 2.7 (95% CI: 1.1–6.5)].28,29   Since 
then many studies have reported a positive relationship between osteoporosis and 
periodontal disease.28,30-33  
To measure bone mineral density (BMD), Jeffcoat et al. used a dual energy x-ray 
absorptiometer (DXA) to measure the hip and quantitative digital radiography to measure 
mandibular bone in 158 postmenopausal women.28,30  They found a significant positive 
correlation between mandibular basal bone and hipbone mineral density (OR: 5.23, 
r=0.74, P<0.01).28,30 Tezal et al. also used DXA to measure skeletal systemic BMD and 
concluded that the mean alveolar bone level significantly correlated positively with 
systemic BMD(r= -0.20 to -0.27) as well as finding a positive correlation between clinical 
attachment levels and BMD (OR: 2.89, r= 0.10 to 0.17).28,31  
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In 1995,Taguchi et al. studied 64 women age 50 to 70 years. The characteristics 
of osteoporosis studied were thoracic spine fracture, and periodontal characteristics 
studied included the number of teeth present, mandibular cortical width and alveolar bone 
resorption.28,32 Their results showed a significant positive correlation with mean alveolar 
bone level and systemic BMD  (Z=18.68-0.29).28,32  Then in 2004, Taguchi et al. 
investigated the effects of estrogen use on tooth retention, oral bone height, and oral bone 
porosity in 264 postmenopausal women.33 Multiple regression analysis showed that the 
duration of estrogen use was significantly associated with number of total (p = 0.019) and 
posterior (p = 0.007) teeth remaining, independent of age and oral bone height suggesting 
that estrogen may be a promoting factor in tooth retention by strengthening the 
periodontal attachment surrounding the teeth, but not increasing oral bone height and not 
decreasing oral bone porosity. 33 
A more recent study by Makker et al. has also shown a positive relationship 
between systemic and alveolar bone loss of the mandible, resulting in tooth loss.34  In 
2012, they concluded tooth loss in postmenopausal women may be an indicator of the 
onset of systemic osteoporosis.34 
In contrast various studies have also shown no relationship between osteoporosis 
and periodontitis.  In 1994, Von Wowern et al. used dual photon absorptiometry on 52 
women with a history of osteoporotic fracture to measure mandibular bone mineral 
content.28,35  They concluded that the osteoporotic women did not have a decrease of 
bone content in their jaw bones [OR: 1.00 (95% CI: 0.98–1.02)].28,35   Lundstrom et al. 
found no statistically significant differences in gingival bleeding, probing pocket depths, 
gingival recession, or the marginal bone level between 15 women with osteoporosis and 
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41 women with normal BMD [OR: 1.3 (95% CI: 0.98–1.02)].28,36  When comparing the 
clinical parameters of periodontitis and alveolar bone height with BMD of the lumbar and 
metacarpal bone, Elders et al. also did not find any statistically significant differences in 
gingival bleeding, probing pocket depths, gingival recession and marginal bone level of 
the subjects with low BMD compared to subjects with high BMD [OR: 1.46 (95% CI: 0.97–
2.21)]28,37 
Skeletal and alveolar bone loss is accelerated by the depletion of estrogen in 
postmenopausal women.9   When a depletion of estrogen causes bone resorption and 
remodeling, tooth support is negatively affected causing an increase in tooth mobility and 
tooth loss.33   A longitudinal study was conducted by Jacobs et al. in 1996 assessing 
lumbar spine bone mineral density of 69 women receiving hormone replacement therapy, 
up to 5 years with dual photon absorptiometry of the lumbar spine.28,38 They concluded 
that estrogen replacement therapy had a positive effect on the bone mass of the mandible 
and the lumbar spine.28,38   
Out of 58 menopausal periodontal maintenance patients that Payne studied, 41 
had normal bone mineral density and 17 were osteoporotic.28,39  The osteoporotic 
estrogen-deficient women showed a greater alveolar bone loss, crestal and subcrestal 
density loss [OR: 1.73 (95% CI: 1.23–2.43)].28,39  Fifty nine women with periodontitis and 
16 non-periodontitis women, all within 5 years of menopause, were subjects in a study 
conducted by Reinhardt et al. that assessed bleeding on probing and clinical attachment 
levels.28,5  The osteoporotic periodontitis patients with estrogen deficiency exhibited a 
greater amount of bleeding on probing and a greater rate of ≥ 2.0 mm clinical attachment 
level loss (3.8% versus 1.2%, 2 P<0.1) than estrogen sufficient subjects.28,5  
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Experimental mice models have also been conducted in order to study the effects 
of estrogen on periodontal disease.7   Skeletal responses of ovariectomy-induced 
osteopenia in mice parallel those of post-menopausal women.7  A 2012 experimental 
study on mice conducted by Kobayashi, et al. concluded that the ovariectomy of mice 
significantly increased alveolar bone loss, suggesting that osteoporosis due to estrogen 
depletion increases alveolar bone loss.10  Studies done by Duarte, et al. have also 
discovered a direct relationship between periodontitis and estrogen deficiency.8 
In summary, many of the above studies have been cross sectional in design using 
a small number of subjects.  Future longitudinal studies will help strengthen the 
preliminary data to help better understand the relationship between postmenopausal 
osteoporosis, estrogen deficiency, and periodontitis.30 Until then, estrogen depletion, low 
systemic bone mineral density and osteoporosis should be viewed as risk factors in 
periodontal disease. 
 
2.6  Bisphosphonates and Periodontal Health 
Bisphosphonates are widely used in the treatment of osteoporosis because of their ability 
to hinder bone resorption facilitated by a decreased function of osteoclasts thus improving 
bone density.40 In diseases such as BCA, bisphosphonates help treat bone pain, improve 
quality of life, and can postpone skeletal events.41   Studies have shown positive effects 
of bisphosphonate use in the treatment of periodontal disease.42-44  Palomo et al. 
conducted a cross-sectional study to investigate the periodontal status of 60 age-matched 
postmenopausal women with mild to moderate osteoporosis.42  The experimental group 
was undergoing systemic risedronate, a bisphosphonate therapy, for 3 months, while the 
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control group never used bisphosphonates.42  Those on the risendronate therapy had an 
overall healthier periodontal status than control subjects exhibiting significant differences 
(p<0.05) in periodontal probing depth (2.6 vs 2.9 mm), gingival index (0.37 vs 0.71), 
plaque score (56.2 vs 77.0), attachment loss (2.8 vs 3.2 mm), and alveolar bone level 
(3.1 and 4.0).42   
Palomo et al. then conducted a longitudinal study investigating the periodontal status of 
28 white postmenopausal women with low bone density using bisphosphonate therapy 
for at least 2 years compared with that of a matching group not using bisphosphonate 
therapy.43  Similar to the cross-sectional study results, women on bisphosphonates 
demonstrated statistically higher plaque score, lower probing depth, and lesser clinical 
attachment loss compared with the controls.43  Although bisphosphonate users exhibited 
lower incidence of bleeding on probing, and lower alveolar bone height, the differences 
were not statistically significant.43 
 
2.7 Calcium and Vitamin D Effects on Periodontal Health 
Peak skeletal bone mass as it increases from infancy to early adulthood is influenced by 
hormonal factors, genetics, diet, exercise, and medications.44  After that period of time, 
bone mass starts to decrease.44  The degree of this increase and loss of bone mass is 
heavily relied on heredity and the availability of calcium.44  Vitamin D promotes the 
absorption of calcium in the intestine while stimulating osteoblasts to support and 
preserve normal bone growth.45  Both calcium and vitamin D are pivotal in the process of 
bone mineralization and the preclusion of osteoporosis.45  1a,25-dihydroxyvitamin, is 
vitamin D’s biologically active form and possesses anti-inflammatory effects by inhibiting 
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the production of cytokine and stimulating monocytes and macrophages to conceal 
peptides with strong antibiotic activity.45 Low levels of vitamin D cause the body to be 
vulnerable to infectious diseases and inflammatory conditions such as periodontitis.45,46   
Miley et al. carried out a cross-sectional study of the effects of vitamin D and 
calcium supplementation on chronic periodontitis on 51 subjects.47 23 subjects were 
taking vitamin D (>or=400 IU/day) and calcium (>or=1,000 mg/day) supplementation. 
Although both groups improved in periodontal health with periodontal maintenance, the 
supplementation group had smaller probing depths, less bleeding on probing, lower 
gingival index values, fewer furcation involvements, less attachment loss, and less 
alveolar crest height loss. The differences between groups approached significance at 
(p=0.08).47 
A study by Garcia et al. also found improvements in periodontal status when both 
vitamin D and calcium supplemental groups and control groups received regular 
periodontal maintenance.45  When collectively looking at clinical attachment loss, bleeding 
on probing, gingival index, plaque index, and furcation, the differences between patients 
who did and did not take supplementation as part of their normal diets was modest 
(baseline (P= 0.061); 6 months (P= 0.049); and 12months (P= 0.114)).45  There was no 
statistical difference found in radiographic measurements of alveolar crestal height 
between groups.45 
It would appear that vitamin D and calcium supplementation is associated with improved 
periodontal health, however further studies are needed to solidify this hypothesis.44-47 
 
2.8 Salivary Biomarker; Osteocalcin 
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 Menopause and its low associated estrogen state is related to an increase in bone 
turnover that is complemented by an increase in bone formation and resorption, thus 
increasing serum bone formation and resorption biomarkers.13  The biomarker osteocalcin 
is a noncollagenous calcium binding protein synthesized in mature human bone mainly 
by osteoblasts.12,48  
 It has been suggested that osteocalcin plays a role in bone resorption and 
deposition.14 While being a specific marker of osteoblast function, osteocalcin in the 
plasma of postmenopausal women has also been known to be the best marker for 
spontaneous bone loss.14  When resorption and deposition are coupled, serum 
osteocalcin is a marker of bone turnover.14  When resorption and deposition is uncoupled, 
serum osteocalcin is a marker for bone formation.14 
The mineralization of bone takes place due to the high attraction osteocalcin has 
for calcium.48  Because of this, it exhibits a compact calcium dependent α helical 
conformation, in which the γ-carboxyglutamic acid (Gla) residues binds and promote 
absorption to hydroxyapatite in bone matrix.48 In osteoporotic women, the formation of 
hydroxyapatite crystals is decreased through a deficiency of calcium and phosphorus. 
When the rate of bone mineralization is decreased, it allows free osteocalcin to be 
available for the circulation in the blood.48 This explains the increase concentration of 
osteocalcin in serum levels of osteoporotic postmenopausal women.48 
Hary Kumar et al. measured forearm, spinal, and femoral bone mineral density 
using dual-energy x-ray absorptiometry and markers of bone formation (serum 
osteocalcin and bone-specific alkaline phosphatase), serum osteocalcin and bone-
specific alkaline phosphatase and bone resorption in 82 postmenopausal women with 
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untreated osteoporosis.49 Serum osteocalcin was significantly different among the 3 study 
groups (4.1 +/- 2.7, 4.5 +/- 3.1, and 6.7 +/- 5.6 ng/mL, respectively; P = .0349) and had a 
significant negative correlation with BMD (r2 = -0.0779; P = .0168) concluding the 
significant correlation of osteocalcin to the bone mineral density in postmenopausal 
women with osteoporosis.49   
Payne et al. examined the relationship between serum biomarkers and bone 
mineral density in 128 post-menopausal women with periodontitis and systemic 
osteopenia.13  The study showed a positive relationship between serum bone biomarkers 
and alveolar bone loss.13  Two-year changes in a serum bone biomarker were significantly 
associated with systemic bone mineral density loss at the lumbar spine (osteocalcin, 
bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025).13   Two-
year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I 
collagen (ICTP; bone-resorption biomarker) were also significantly associated with 
alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008).13   
More importantly, this study showed osteocalcin as a sensitive biomarker for alveolar 
bone loss. 13   
Makker et al. also concluded a strong positive statistical correlation between 
osteocalcin, systemic bone mineral density, and mandibular bone mineral density 
demonstrating osteocalcin levels of postmenopausal women are strong predictors of 
mandibular bone mineral density.34    
2.9 Whole Saliva Sampling 
Osteocalcin has been detected in whole saliva samples and GCF.50,51 Using 
whole saliva collection methods to measure the biomarker osteocalcin is a fast and 
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convenient way to obtain samples. Whole saliva samples are potentially an overall 
representation of all periodontal sites providing an overall picture of a subject’s 
periodontal disease status.50,51 
Despite the advantages of whole saliva collection, the technique does have its 
limitations such as; the possible destruction of immunodeterminants necessary for 
immunoassay by the inhibitors or enzymes in saliva, the elevation of proteases in the 
saliva of periodontal subjects, which can ultimately decrease levels of protein 
biomarkers, subject oral hygiene, level of xerostomia, and variations in salivary flow 
rate.50,,52-54    A great amount of information regarding bone turnover specifically in the 
peridontium can be obtained through gingival crevicular fluid (GCF) samples, but this 
method can be time consuming and mirror gingival inflammation for the tested site 
only.14,50 
Whole saliva methods have been used in studies to determine salivary 
biomarkers responsible for alveolar bone loss in postmenopausal women. A study by 
Scannapieco et al. provided preliminary evidence that several salivary biomarkers 
measured at baseline may serve to predict future alveolar bone loss.55 
McGehee et al. used whole saliva samples to determine whether salivary 
concentrations of osteocalcin were statistically correlated with BMD. Results suggested 
that salivary osteocalcin concentrations could be used to predict both osteopenia and 
osteoporosis in human participants, as they positively correlated with calcaneal T 
scores.56 
 
Conclusions and Recommendations: 
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 Due to the advancements in cancer medicine such as early detection and 
treatment, more and more women are surviving breast cancer.15  Aromatase inhibitors 
are becoming the gold standard of treatment for post-menopausal women with breast 
cancer, especially because their ability to lower the risk of tumor recurrence.18  However, 
the use of AIs are associated with estrogen depletion and increased incidence of 
osteoporosis.  Given the relationship between estrogen depletion, osteoporosis, and 
periodontitis, it is uncertain as to what the oral side effects of aromatase inhibitors are.  
Therefore this study aimed to determine the effects of aromatase inhibitors on the 
periodontium.  Knowledge regarding the impact of AIs on periodontal health will aid in the 
appropriate oral and overall health care of these patients and help create a better 
standard of care for future patients. This knowledge will lead to an improved risk 
assessment of oral and overall health care of these patients and ultimately may lead to a 
better standard of care for future patients.   Finally, this study will also provide a basis for 
further research on the oral effects of aromatase inhibitors. 
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Chapter III 
Materials and Methods 
 
3.1 Data Source  
Data for this analysis was extracted from a 2009 18 month prospective cohort pilot 
study examining the oral health of 58 post-menopausal women (29 AI treatment group 
subjects and 29 control group subjects).  This study was undertaken following IRB 
approval at the University of Michigan. Clinical dental data, standardized radiographs, 
oral fluid specimens, survey data on demographics, and perceived oral health were 
collected from all participants.  Diagnosis date, cancer treatments, co-morbid conditions, 
and medication use was obtained from the patient’s medical chart.  The subjects did not 
undergo or receive any type of treatments.   
 
Patient Recruitment 
The recruitment of AI treatment group subjects was done by the University of 
Michigan Breast Care Center (UMBCC) Oncology Team.  Control subjects were recruited 
through flyers approved by the institutional review board (IRB) posted within the 
University Campus and greater Ann Arbor Area, University of Michigan’s Engage 
Website, the Clinical trials.gov website, the MCHOR website as well as at the University 
of Michigan Breast Imaging clinic (UMBI) for mammograms.  The study consisted of 29 
AI treatment group subjects and 29 control group subjects.  The number of participants 
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for the study was determined through a power analysis. This sample size was chosen to 
meet recruiting feasibility limits. Based upon longitudinal pilot data of CAL in non-cancer 
patients, the sample size allowed for at least 80% power (with a Type I error rate of 5%) 
to detect a 10-point difference (i.e .20 vs. .10) in the 18 month change in percentage of 
sites with 3mm or more of CAL between the two groups of subjects (AI therapy vs. 
control). A single sample size that meets the power requirements for all hypotheses listed 
was calculated, but it was acknowledged, that statistical analysis may have been 
restricted by the sample size to a limited number of predictor variables for certain 
statistical models. 
 
Eligibility  
The following eligibility criteria were laid out for the 2009 prospective study. 
Inclusion Criteria:   
Postmenopausal as defined by National Comprehensive Cancer Network (any of the 
following) 
• Prior bilateral oophorectomy 
• Age equal to or greater than 60 years of age 
• Age less than 60 and amenorrheic for 12 or more months in the absence of 
chemotherapy, tamoxifen, toremifen or ovarian suppression and FSH and estradiol 
in the postmenopausal range. 
• If taking tamoxifen or toremifen and age less than 60y, then FSH and plasma 
estradiol level in postmenopausal ranges. 
• Informed consent-  Individuals capable of consenting and self-administering the 
survey instrument.  
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• Dentate- At least 15 teeth present. 
AI users: 
• Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III 
with no evidence of metastatic disease.  
• Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or 
letrozole). Subjects may have had prior tamoxifen or raloxifene.  Subjects may 
have had chemotherapy and/or radiation therapy.  
Controls: 
• No Diagnosis of cancer- Patients must not have a diagnosis of any cancer. 
Exclusion Criteria: 
Medical history: 
• Metastatic BCa (AI treated group: fully resected locally recurrent disease is 
permitted if the patient has been rendered without evidence of disease).  
• Significant psychiatric illness/social situations that would preclude 
completion of questionnaire. 
Medications: 
• Chronic medications known to affect the periodontal status (calcium 
antagonist, anti-convulsives, immunosuppresives (> prednisone 7.5mg 
daily). NSAIDS and bisphosphonates are permitted.  
 
Data Collection Procedures   
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Data were collected using both questionnaire and clinical examinations.  
Questionnaire: Participants responded to self-report questionnaires at baseline, 6, 12 
and 18 months. The questionnaire was completed with study personnel at the time of oral 
examination. The questionnaire included questions concerning the respondents’ (a) 
demographic background such as their age, ethnicity/race, marital status, number of 
children, education, and income, (b) self-reported oral health such as the presence or 
absence of oral problems, self-perception of oral health, pain, dry mouth, and tooth loss, 
(c) dental care utilization such as their dental insurance status, the frequency of dental 
visits, reasons for not utilizing dental care services, dental consultations prior to breast 
cancer treatment, information given to patients concerning oral side effects of cancer 
therapy and oral hygiene self-care, (d) psychological factors such as depression and 
stress, and (e) lifestyle factors, namely use of tobacco and alcohol. [see appendix A for 
questionnaire].   
Confidentiality was assured by assigning each survey a unique identification 
number. Only the PI, the research team, and statistician had access to the database.  
Chart review: Patient charts were obtained and reviewed to extract information regarding 
cancer diagnosis, diagnosis date, cancer treatments, all other medical conditions, and a 
current medication list. [see appendix B for chart data abstraction sheet] 
Clinical Data Collection Procedures 
Examination Procedures:  All dental examinations were performed at the Michigan 
Center for Oral Health Research (MCOHR) located at Domino’s Farms. Dental 
examinations were done at baseline, 6, 12, and 18 months.  
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The examiner was a registered dental hygienist blinded to the cohort’s group 
status. After the completion of inclusion and exclusion criteria, The examiner completed 
a full mouth standard comprehensive periodontal examination, including periodontal 
pocket depth, gingival recession, CAL, bleeding upon probing, plaque scores, missing 
teeth and supragingivial  (above the gum line) plaque assessment on all teeth in each 
subject. Probing depths were measured with a University of North Carolina periodontal 
probe. Probing depth was measured on 6 sites per tooth.  The loss of clinical attachment 
was defined as the distance in mm from the cemento-enamel junction to the base of the 
periodontal pocket. Probing depth was the distance from the free gingival margin to the 
base of the sulcus/pocket that could be probed. Distance was recorded to the next lowest 
millimeter. [see appendix C for the periodontal report form and clinical case report form.] 
Standardized Radiographs: To measure changes in alveolar bone over time, two 
periapical radiographs, each positioned to visualize the premolar area in the mouth, were 
taken using F-speed #2 size intra-oral film at baseline 12, and 18 months. These x-rays 
are associated with 2 milli Severts of radiation which is a minimal amount of exposure for 
the patient and clinically not significant. All films were taken using an extended geometry 
method.57,39  This technique assures that consistent projection geometry was achieved 
for each follow-up examination. 
Whole Saliva Collection: To determine whether AI therapy increases bone remodeling 
biomarkers, osteoprotegerin (OPG) and osteocalcin was examined in the saliva of AI and 
non AI users at baseline, 12 and 18 months.  Unstimulated whole saliva was collected 
from each subject as previously described by Mandel.58 The procedures were stopped 
once a total of 2ml was collected or 15 minutes had elapsed. The sample was placed on 
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ice, aliquoted, and supplemented with two proteinase inhibitors (Aprotinin (1mg/ml) at a 
dilution of 1:100 and Phenylmethylsulphonyl fluoride (PMSF) (100 mM in MeOH) at a 
dilution of 1:200) and stored at -80 C.   
Examiner Training and Calibration Session: 
Prior to the start of the study, all study examiners attended a calibration session to ensure 
accuracy of data collection for all clinical parameters, which should increase intra and 
inter-rater reliability.  
Human Subjects 
Protection of Human Subjects: IRB approval was attained at the University of Michigan. 
The study utilized an informed consent procedure. Medical risks resulting from this 
research were extremely low. The study collected standard clinical dental data, clinically 
collected oral saliva specimens at relevant times and gathered materials from patient 
medical records. 
The risk of breach of confidentiality of personal health information was present and was 
considered to be low due to safeguards implemented with the removal of patient 
identifiers and the use of secure databases, restricted access. Investigators and staff 
were well trained in the conduct of clinical research.  
 The procedures for protecting against potential risks, including risks of privacy and 
confidentiality included removing identifiers from the study specimens, securing data in 
password protected electronic database Velos systems with limited access and security 
software and working within organized institutions with staff well trained in the protection 
of human subjects. There was a very high likelihood that these procedures would 
minimize risk.   Events were not expected to occur often and would be handled on an 
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individual basis. Should a breach have occurred, it would be investigated and the situation 
corrected. In the unlikely chance that a breach of confidentiality occurred, the IRB would 
be notified and the investigators would respond to the guidance provided by the IRB.  The 
privacy of all participants was protected under HIPPA provisions. 
 The same procedures for protecting against potential risks of privacy, confidentiality, 
and breach of confidentiality were carried out for the secondary analysis.   
 
Serious Adverse Event (SAE) Reporting: No Data Safety Monitoring Board was 
proposed for the primary correlative study as it was not applicable. Although SAEs were 
not anticipated to occur within this study of oral exam and questionnaires, should any 
SAE have occurred, it would be reported to the IRB as soon as possible but no later than 
7 days from coming to the attention of the investigator. The Study Team reviewed the 
protocol progress weekly with attention to accrual rate and safety issues. 
 
Informed Consent Procedures: All patients participating in this study were required to 
sign a statement of informed consent prior to participation in the study that included; the 
nature and purpose of the proposed study and the possible benefits to the patient, the 
length of the treatment and follow up required, risks or discomforts involved, alternatives 
to proposed study, name of the investigator(s) responsible for the study, right of the 
patient to accept or refuse treatment and to withdraw from participation in this study at 
any time, and a statement that the patient’s confidentiality would be maintained. The 
informed consent document was reviewed with the patient prior to obtaining consent, and 
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a signed copy of the consent was provided to the patient, filed in a medical record and 
provided to the MCOHR Office. 
 
Subject registration: After completing screening and informed consenting, the patient 
was registered thorough the MCOHR office. Each patient was assigned a clinical study 
registration number which served to code their specimens and clinical data. 
 
3.2 Materials and Methods for Secondary Data Analysis 
 Using the described prospective cohort study above we tested the following 
hypotheses; Hypothesis1: Postmenopausal breast cancer survivors who are on adjuvant 
aromatase inhibitors will exhibit an increase in clinical attachment level, probing depths, 
bleeding on probing, and a radiographic decrease in bone height as compared to those 
postmenopausal women who are not receiving adjuvant aromatase inhibitor treatment. 
Hypothesis 2: Postmenopausal breast cancer survivors on adjuvant aromatase inhibitors 
will exhibit a higher level of osteocalcin as compared to those postmenopausal women 
not on adjuvant aromatase inhibitors.  Hypothesis3: When controlling for demographics, 
we expect to see a difference in the effects supplemental bisphosphonate, vitamin D, and 
calcium use between postmenopausal breast cancer survivors on aromatase inhibitors 
and postmenopausal women not on aromatase inhibitors.  The implementation of this 
study and the results of the secondary analysis will provide insights into alveolar bone 
loss as a side effect of adjuvant AI in postmenopausal women with breast cancer. 
 
  
  
30 
 
Alveolar Bone Loss: To determine the changes of the periodontium as measured 
through the clinical periodontal parameters of CAL, PD, BOP, and linear radiographic 
measurements in postmenopausal breast cancer survivors on adjuvant aromatase 
inhibitor therapy  compared to those postmenopausal women who did not receive 
adjuvant aromatase inhibitor therapy, a mean of CAL, PD, and BOP from the overall study 
was analyzed to determine the changes of alveolar bone loss. Utilizing the standardized 
radiographs taken from the previously described cohort study, the presence or absence 
of alveolar bone loss over time was determined using the Image J software program.  
Radiographs were transferred from the MCOHR facility to the University of Michigan 
Dental School by downloading all patient radiographs on a secure electronic server.  
Linear measurements between the cemento-enamel junction or restoration margin, and 
the alveolar crest of first molars were made on baseline, 12 and 18 months radiographs. 
Two separate linear measurements were taken at all time points, and the average of both 
measurements was recorded.  All radiographs were analyzed by a single calibrated 
examiner.  All measurements were calibrated by the measurement of the inserted step-
wedge. In order to set the measurement scale, vertical measurements of the step wedge 
were taken from 5 separate radiographs.  The average of the measurements determined 
the distance in pixels value. The Measured known distance of the step wedge was 5.0mm 
and the pixel aspect ratio was 1.0.  Unit of length used was millimeters. Alveolar bone 
loss was defined as a 0.4mm or greater reduction in bone height.   
 
Salivary Biomarkers: In order to determine whether breast cancer survivors on 
aromatase inhibitors exhibit an increase in alveolar bone loss as measured through the 
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salivary biomarker osteocalcin, whole saliva was analyzed. The previously collected 
frozen samples were thawed at room temperature. Saliva OPG and osteocalcin levels 
were quantified in cell-free supernatants by ELISA (Osteoprotegerin; ALPCO 
Diagnostics, Salem, N.H., Osteocalcin ELISA; BTI, Stoughton MA).59 Total protein levels 
were used to normalize the values (Sigma, St. Louis MO). Protein levels were compared 
to the clinical data including CAL, pocket depths, and radiographic data. All laboratory 
analyses were performed by a laboratory technician at the Russell Taichman laboratory 
in the University of Michigan, School of Dentistry.   
Demographics, Bisphosphonates and Supplementation: To determine whether 
patient demographics and the use of bisphosphonates, vitamin D, and calcium have a 
differential impact on alveolar bone loss among postmenopausal breast cancer 
survivors on aromatase inhibitors as compared to postmenopausal women not on 
aromatase inhibitors:  Data regarding subject age, ethnicity, marital status, education, 
smoking status, dental utilization, and dental insurance status was extracted from the 
survey questionnaire.  Data regarding use of bisphosphonates, vitamin D and calcium 
supplementation was extracted from the survey questionnaire and medical charts to 
examine if the interaction of aromatase inhibitors in the presence of these supplements 
caused an effect on alveolar bone loss.   
Age was collected as a continuous variable.  AI status, marital status, dental 
insurance status, alcohol consumption, diabetes status, and current tobacco use were 
collected as categorical variables.  Subjects answered yes or no for each question.  
Ethnicity was defined as white or non-white. 
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Education was collected as a categorical variable.  The variable was defined as 
“some college or more” and “high school or less”.  Income was collected as a categorical 
variable.  The variable was defined as “no income- $19,999”, “$20,000-$39,999”, 
“$40,000-$59,000”, $60,000-$74,999”, and “over “$75,000”.  Employment status was 
collected as a categorical variable.  The variable was defined as “working full-time”, 
“working part-time”, “not actively employed”.  Bisphosphonate, calcium, and vitamin D 
supplementation were recorded as categorical values.  Each subject answered a yes-1 
or no-0 based on their supplement use at baseline.  
 
Statistical Analysis Plan 
 Statistical analyses were done taking into account the study design and number of 
subject participants. Univariate statistics were calculated for continuous variables and 
frequency tables were generated for categorical variables.  Independent sample t tests 
were done to investigate the differences of alveolar bone height between groups at each 
time point, the effects of bisphosphonate, calcium, and vitamin D supplementation on 
alveolar bone height between groups at each time point, as well as mean CAL, PD, and 
BOP.  Paired t tests were done to investigate intragroup changes for bone height, CAL, 
PD, and BOB.   Linear Pearson Correlation Coefficients were used to look at the 
correlation between salivary osteocalcin and bone height between groups.  Linear mixed 
models were constructed to investigate bone height as a function of time, AI use, calcium, 
vitamin D and bisphosphonate status, along with an interaction between AI and calcium 
status. Data analysis was performed using the statistical package IBM SPSS. 
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Chapter IV 
Results 
 
Figure 4.1 provides an overview of the study participant recruitment and 
enrollment.  Potential participants assessed for eligibility were n=142.  Of the 142 eligible 
participants, 26 were excluded because they did not meet inclusion criteria and 45 
declined to participate.  A total of 63 study participants were enrolled, 29 control subjects, 
and 34 AI treatment subjects.  Prior to baseline examination, 5 AI treatment subjects 
withdrew from the study n=29.  After the baseline visit, 1 AI treatment subject withdrew 
and after the 6 month visit, 3 AI treatment subjects withdrew resulting in 25 study 
participants.  There were no withdraws among the control subjects.  
Among the 58 study participants, 29 were taking aromatase inhibitors and 29 were 
not. The age range of study participants was 44-75 years old. and the mean age of study 
participants was 61.66 years old. The majority of the study participants were Caucasian 
89% (n=52) and 67.2% (n=39) were married.  Approximately 66% of women (n=38) 
reported having some college education or more, while 33% (n=19) reported having a 
high school or less than high school education. Of the 58 study participants, 60.3% (n=35) 
reported drinking alcohol, 3.4% (n=2) were current tobacco users, and 8.6% (n=5) had a 
health history of diabetes.  Slightly over half the study participants,   51.7% (n=30) were 
not actively working, 19% (n=11) working part time, and 29.3% (n=17) were full time 
workers.  An income of over $75,000 was reported by 36.2 (n=21) 
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participants, 37.9% (n=22) reported an income of $20,000-$75,000, while 22.4% (n=13) 
reported an income of $19,000 or less.  Forty-four women (75.9%) reported having dental 
insurance.  At baseline, 27.6% (n=16) study participants were taking bisphosphonates, 
53.4 (n=31) taking calcium supplements, and 58.6% (n=34) taking vitamin D.    Of the 58 
enrolled participants, 53 participants completed the study.  Of the 53 participants, 24 were 
taking aromatase inhibitors and 29 were not.  
Table 1 provides demographic characteristics of study participants broken out by 
AI status at baseline.  The statistics for participants on AI and not on AI (controls) were 
similar for all categories.  The average age for both groups was 61+ years.  Both groups 
were comprised of nearly 90% (n=26) Caucasians.  Income, education levels, and dental 
insurance status were also similar for both groups. 
A descriptive summary of linear alveolar bone height by AI status is provided in 
Table 2.  An increasing value for alveolar bone height from each time point indicates a 
greater loss of alveolar bone and the subject’s periodontal status is worsening.  The 
average difference in bone height from baseline to 18 months for participants on 
aromatase inhibitors was 0.32mm ± SD 0.36, indicating a decrease of about 0.32mm over 
the course of the study.  Similarly, the average difference in bone height from baseline to 
18 months for participants not on aromatase inhibitors was a decrease of 0.25mm ± SD 
0.22. The difference in bone height from baseline to 18 months was not statistically 
different comparing those on AI and those not on AI (t(df)= 0.80(48), p=0.42). No 
statistically significant differences were found between the groups for average bone 
height at baseline, 12, or 18 months.  When looking within the groups, the difference in 
bone height from baseline to 18 months was significantly different for those on AI (t(df)= 
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4.081(20), p=0.001, as well as the difference in the 12 to 18 month time point (t(df)= 
3.504(20), p=0.002 (Table 3).  Those not on AI showed a statistical difference in bone 
height between each time point (Table 4). 
A descriptive summary of the average clinical attachment level (CAL) broken out 
by AI status is provided in Table 5.  The mean CAL at baseline for participants not on AI 
was 1.42 ± SD 0.39.  Similarly, the mean CAL for these participants at 18 months was 
1.45 ± SD 0.20. The mean CAL of study participants on AI at baseline was 1.51 ± SD 
0.75, and 1.84 ± SD 0.40 at 18 months.  Comparing those on AI therapy and those not 
on AI therapy showed no statistical difference at baseline (t(df)=0.58(56) p=0.56).  
However there was a statistically significant difference between those on AI and those 
not on AI at 6 (t(df)= 3.23(54) p<0.001), 12 (t(df)= 3.43(50) p<0.001), and 18 months 
(t(df)= 4.53(50) p<0.001). Tables 6 and 7 are a summary of the average CAL over time 
within groups. In general, a statistical difference in CAL was also seen when looking over 
time within the groups.  There was a statistical difference in CAL for those on AI between 
baseline and 6 months (t(df)= 2.990(26), p=0.006), baseline and 12 months (t(df)= 
4.489(22), p<0.001), and baseline and 18 months (t(df)= 5.705(22), p<0.001).  For those 
not on AI, the only statistical difference in CAL was at the baseline to 6 month time point 
(t(df)= 2.627(28), p= 0.014). 
A descriptive summary of the average probing depth measurement (PD) broken 
out by AI status is provided in Table 8.  The mean PD at baseline for participants not on 
AI was 2.00 + SD 0.29. Similarly, the mean PD for these participants at 18 months was 
2.00 + SD 0.19.  The mean PD for study participants on AIs at baseline was 2.00 + SD 
0.27 and 2.26 + SD 0.30 at 18 months.  When comparing PD for those on AI and not on 
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AIs there were statistical differences at 6 months (t(df)= 4.49(54) p< 0.001), 12 months 
(t(df)= 3.10(50) p=0.01), and 18 months (t(df)= 3.72(50) p<0.001).  When looking at 
differences between baseline and 18 month time points for those on AI and not on AIs, a 
significant difference was also found (t(df)= -3.96(50), p<0.001).  Participants on AIs had 
higher PD measures at each time point.  No significant differences between the groups 
were found for average PD at baseline. Intragroup analysis showed a statistical difference 
in PD over time for those on AI between baseline and 12 months (t(df)= 3.355(22), 
p=0.003), as well as baseline and 18 months (t(df)= 4.756(22), p<0.001) (Tables 9 and 
10). 
A descriptive summary of average bleeding on probing (BOP) broken out by AI 
status is provided in Table 11.  The mean BOP at baseline for participants not on AI was 
0.107 + SD 0.080. The mean BOP for these participants at 18 months was 0.148 + SD 
0.132.  For those on AI, mean BOP at baseline was 0.176 + SD 0.141and 0.198 + SD 
0.121at 18 months.  When comparing BOP for those on AIs and not on AIs, there were 
statistical differences at baseline (t(df)= 2.288(44.250), p= 0.027, 12 months (t(df)= 
2.734(50), p=0.009, and when looking at the difference between baseline and 18 months 
(t(df)= 3.247(39.237), p=0.002.  Interestingly, within groups, BOP was statistically 
significant over time at each time point for those not on AIs and statistically significant at 
baseline to 12 months for those on AIs (t(df)= 2.351(22), p= 0.028 (Tables 12 and 13). 
Table 14 illustrates the effects of vitamin D use on alveolar bone height for those 
on AI while Table 15 illustrates its effects on alveolar bone height for those not on AI. The 
average difference in bone height from baseline to 18 months for participants on AI and 
vitamin D was 0.31 + SD 0.32, indicating an increase of about 0.31mm over the course 
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of the study.  Similarly, the average difference in bone height from baseline to 18 months 
for participants on vitamin D and not on AI was an increase of 0.24 + SD 0.20. The 
difference in bone height from baseline to 18 months was not statistically different for 
those on AI and vitamin D (t(df)= 0.65(16), p=0.52). For those on AI, the average bone 
height at baseline, 12 months, and 18 months did not differ significantly between those 
on vitamin D and those not on vitamin D. Further, for those not on AI, average bone height 
at baseline, 12 months, and 18 months did not differ significantly between those on 
vitamin D and those not on vitamin D. 
Table 16 illustrates the effects of calcium use on alveolar bone height for those on 
AI while Table 8 illustrates its effects on alveolar bone height for those not on AI. The 
average difference in bone height from baseline to 18 months for participants on AI and 
calcium was 0.26 + SD 0.34, indicating a decrease of about 0.26mm over the course of 
the study.  The average difference in bone height from baseline to 18 months for 
participants on calcium and not on AI was a decrease of 0.21 + SD 0.12.  For those on 
AI, the average bone height at baseline (t(df)= -2.56(17), p=0.02), 12 months (t(df)= -
2.44(16), p=0.03), and 18 months (t(df)= -2.13(16), p=0.05) differed significantly between 
those on calcium and those not on calcium.  The difference in bone height from baseline 
to 18 months was not statistically different for those on AI and calcium (t(df)= -0.27(16), 
p=0.78). For those not on AI, average bone height at baseline, 12 months, and 18 months 
did not differ significantly between those taking calcium and those not taking calcium 
(Table 17).  
Table 18 illustrates the effects of bisphosphonate use on alveolar bone height for 
those on AI while Table 10 illustrates its effects on alveolar bone height for those not on 
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AI. The average difference in bone height from baseline to 18 months for participants on 
AI and bisphosphonates was 0.08 + SD.27, indicating a decrease of about 0.08mm over 
the course of the study.  The average difference in bone height from baseline to 18 
months for participants on bisphosphonates and not on AI was a decrease of 0.20 + SD 
0.14.  For those on AI, the difference in bone height from baseline to 18 months was 
significantly different for those on bisphosphonates compared to those not on 
bisphosphonates (t(df)= -2.12(16), p=0.05).  We did not see significant differences for 
those on AI at baseline, 12, and 18 months for those on bisphosphonates compared to 
those not on bisphosphonates.  For those not on AI, average bone height at baseline, 12 
months, and 18 months did not differ significantly between those on bisphosphonates and 
those not on bisphosphonates. 
A linear mixed model (Table 20-24) was constructed to investigate bone height as 
a function of time, AI, calcium, vitamin D and bisphosphonate status, along with an 
interaction between AI and calcium statuses.  Linear mixed models account for the 
dependence in the data due to repeated measures per study participant. When controlling 
for the other variables in the model, a significant effect of time was found along with a 
significant AI status by calcium use interaction. Those on AI and calcium have a 
significantly lower bone height value (Est. Mean=2.50, SE=0.13) than those on AI but not 
on calcium (Est. Mean=3.32, SE=0.23) (p=0.005) but no significant difference was found 
between those on calcium and those not for those not on AI. Bone height decreased 
significantly over time when controlling for the other covariates in the model.                                                                          
Table 25 illustrates salivary osteocalcin levels for those on AI and controls.  There 
was no statistical difference in salivary osteocalcin levels between the two groups at 
  
  
40 
 
baseline t(df)=-.31(54) p=0.76, 12 months t(df)= 1.36(44) p= 0.18, and 18 months t(df)= -
0.57(45) p=0.23.  When looking at the correlation between salivary osteocalcin and bone 
height, there was no significant relationship at baseline, 12, and 18 months using Pearson 
Correlation Coefficients (Tables 26,27). 
  
  
41 
 
Chapter V 
 
Discussion 
 
  The aims of this study were to examine the changes of the periodontium as 
measured through the clinical periodontal parameters in postmenopausal breast cancer 
survivors on adjuvant AI as compared to those not on AI.  Secondary aims of this study 
were to determine if these women exhibit a decline in the periodontium as measured 
through the salivary biomarker osteocalcin, and whether patient demographics and the 
use of bisphosphonates, vitamin D, and calcium supplements have a differential impact 
on alveolar bone loss. This investigation suggests that adjuvant AI therapy does have an 
impact on the oral health of postmenopausal women on AIs.  Furthermore, in 
postmenopausal women on AIs, calcium supplementation decreases alveolar bone loss.  
The results also suggest that clinical attachment levels, BOP and PD increase over time 
in postmenopausal women on AI’s.   
 
 Periodontitis is an inflammatory disease characterized by the loss of alveolar bone 
and clinical attachment loss of the soft tissues while osteoporosis is characterized by 
bone loss leading to structural bone transformation.4,6  Osteoporotic changes have been 
seen in the oral cavity as a loss of alveolar bone, causing it to be a provoking component 
in periodontal disease.8    
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 Previous investigations have illustrated the advantageous effects of hormone 
replacement therapy on clinical attachment levels.60,5  A longitudinal study by Reinhardt 
studied 59 osteoporotic postmenopausal women, and found that estrogen 
supplementation was associated with less clinical attachment loss.5  Our group of 
postmenopausal women taking AI showed significant differences compared to 
postmenopausal women not taking AI for average CAL and PD at 6,12, and 18 months, 
and also when looking at the difference in CAL and PD from baseline to 18 months.  When 
looking within groups, we also saw significant differences over time for CAL and PD for 
those women on AI.  This suggests AI causes a negative effect on CAL and PD that 
increases with time.  In a cross-sectional study, Aspalli et al. concluded a definite 
relationship between osteoporosis and periodontitis based on PD and CAL.61  As the BMD 
decreases, the PD and CAL increases.61  Shen et al. also suggests osteoporosis is a risk 
factor for periodontitis after finding an increase in attachment loss in osteoporotic 
subjects.62  Using the NHANES III data, Ronderos et al. in a found that women with high 
calculus index and low BMD had significantly more CAL than women with a similar 
calculus index and normal BMD.63 
 Studies have shown that postmenopausal women on bisphosphonates have 
improved periodontal disease and bone turnover including those with osteoporosis.42,43,65 
Postmenopausal subjects on bisphosphonates demonstrated a significantly less plaque 
accumulation, less gingival inflammation, lower probing depths, less periodontal 
attachment loss, and greater alveolar bone levels, suggesting that bisphosphonate 
therapy may play a beneficial role in periodontal status.42  When investigating the effects 
of bisphosphonate supplementation on alveolar bone loss, we saw no significant 
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differences for those postmenopausal women taking AI and bisphosphonates at baseline, 
12, and18 months as compared to those taking AIs and not taking bisphosphonates.  We 
did, however see an overall statistical significance in those on AIs and bisphosphonates 
when looking at the difference in bone height from baseline to 18 months t(df)= -2.12(16) 
p= 0.05.  For postmenopausal women not on AI, average bone height at baseline, 12 
months, and 18 months did not differ significantly between those on bisphosphonates and 
those not on bisphosphonates.  For postmenopausal women not on AI, average bone 
height at baseline, 12 months, and 18 months did not differ significantly between those 
on bisphosphonates and those not on bisphosphonates.  As the sample size for this pilot 
study was small, it may have impacted our ability to detect a significant difference in 
bisphosphonate use.   Further longitudinal studies with larger sample size should be done 
to gain a better understanding of the relationship between bisphosphonate use and 
alveolar bone loss among AI users.  
 Although sustaining ideal levels of calcium and vitamin D is essential for 
maintaining bone in postmenopausal women, there are limited studies documenting their 
role in periodontal health.66,67  Based on data from the 3rd National Health and Nutrition 
Examination Survey (NHANES III), Dietrich et al. found a significant correlation between 
vitamin D levels and clinical attachment loss in both men and women over the age of 
50.67,68 Those on vitamin D had lower clinical attachment loss than those not on vitamin 
D.  Dietrich et al. also  determined an association between low vitamin D serum levels 
and an increase of bleeding on probing establishing the positive anti-inflammatory role 
vitamin D plays in gingival inflammation and periodontitis.67,68  This investigation did not 
find the supplementation of vitamin D to have a significant effect in bone height in either 
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the AI or control groups.  In a 7 year prospective study of 62 year old men, Krall showed 
no link between vitamin D and alveolar bone loss, however the authors did find a 30% 
higher loss of alveolar bone among those men with low calcium levels.66,67  Evidence 
suggests increased levels of calcium are positively correlated with a reduced prevalence 
of clinical attachment loss and a lower risk of tooth loss.66  Utilizing the NHANES III data, 
Nishida et al. found subjects with inadequate calcium levels exhibited more severe 
periodontal disease.67,69  This study showed significantly lower bone height values for 
postmenopausal women taking AI and calcium supplements compared to those taking AI 
but not taking calcium.  AI users supplementing with calcium exhibited less bone loss at 
baseline and each subsequent time point than those AI users not taking calcium; 
however, there was no significant difference between these groups in bone height change 
from baseline to 18 months. One explanation for a non-significant finding is the loss to 
follow up that occurred within the AI group impacting 18 month measures (loss to follow 
up n=4). This loss of participants may have affected the ability to detect a difference in 
bone height.   Millen et al., conducted one of the largest prospective study on the effects 
of vitamin D on the advancement of periodontal disease in postmenopausal women.70  
The authors did not note an association between vitamin D status and  alveolar bone 
height as well as CAL, PD, and gingival bleeding.70  The cohort of postmenopausal women 
in the Millen study did not have a high prevalence for periodontal risk factors such as 
smoking, as in our study.70 As there is conflicting evidence available, there is a need to 
conduct randomized controlled clinical trials to determine the effects of both vitamin D 
and calcium supplementation on alveolar bone loss.  Evidence from studies has linked 
an association between calcium use and an increased risk for cardiovascular events 
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among patients undergoing chemotherapy.71,72  Advice about supplement use, such as 
calcium, needs to be individualized and come from a credible source, and it is best 
communicated by the physician.   
This study did have some limitations. First, subjects initially had minimal 
periodontal attachment loss and changes in both groups for PD and CAL, though 
statistically significant, were of small magnitude. Thus, the effect size was relatively small. 
Although we saw statistically significant changes in linear radiographic bone height over 
time when looking within groups for both women on AI and not on AI, the investigation, 
as originally hypothesized did not show a difference in alveolar bone height between the 
two groups of postmenopausal women.  When looking at table 2, if one subtracts the 
baseline mean alveolar bone height from the 18 month alveolar bone height, the 
difference (2.86-2.67=0.19mm) does not agree with the reported difference of 0.32mm 
because the computed mean difference was based on sample sizes for those on AI that 
varied slightly over time because of the withdrawal of AI users due to drug toxicity.  In 
addition, we may not have seen any changes in bone height because the accuracy of the 
linear measurements may be have been limited by the ununiformed technical quality of 
the x-rays and unintentional differences in x-ray techniques.  Although a beam guiding/ 
positioning device, bite registration, and step wedge were used, the film placement varied 
and both vertical and horizontal images were taken.  If radiograph placement had been 
uniform, subtraction radiography may have been possible.  Digital subtraction 
radiography is a technique used to determine both qualitative yes/no results and 
quantitative results expressed in absolute units, mg of bone, or relative units in the 
changes that occur between two or more images taken at different points in time.73  
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Subtraction radiography  has been suggested to be a  more diagnostically accurate way 
to identify alveolar bone change compared to conventional x-ray techniques.74  Perhaps 
the use of a vertical posterior bitewing compared to a posterior periapical may have made 
the linear measurements more accurate.  Overall, both the control and AI subjects 
presented with mild disease to a fairly healthy periodontium.  It is difficult to determine in 
such a small and healthy population whether or not AI is affecting alveolar bone height, 
especially since we have not provided any type of oral health treatment for these women.   
When measuring osteocalcin levels, the investigation also did not show a 
difference in alveolar bone height between the two groups of postmenopausal women.  
Many women who were taking AIs were unable to give a saliva sample.  We had 1 missing 
sample at baseline, 10 at 12 months, and 11 at 18 months.  It was difficult to determine 
whether the dry mouth was a side effect of their AI therapy or other medications that might 
have a side effect of xerostomia such as antidepressants, antihistamines, and 
medications that that treat high blood pressure and heart conditions.  The number of 
missing saliva samples coupled with the loss of AI users at the 12 and 18 month time 
point may have affected our ability to find a correlation between the salivary biomarker 
osteocalcin and bone height.  Although whole saliva samples are an overall 
representation of all periodontal sites providing an overall picture of a subject’s 
periodontal disease status, GCF samples provide a great amount of information regarding 
bone turnover specifically in the peridontium, and may have been easier to collect, 
especially in women who could not produce whole saliva samples.50,51,14   
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As this was a pilot study the sample size was small.  Beginning trends in bone loss 
may have been seen, but may not have had enough power to detect a difference or 
perform more advanced statistical analysis.    
However, this study had some notable strengths including the comprehensive 
periodontal examinations and detailed demographic and cancer information.  Although 
the sample size was small, there were power calculations for the primary endpoint.   
This study is among the first to investigate the oral effects of AI on postmenopausal 
women with breast cancer.  The results from this study indicate those on AI experience 
greater increases in CAL, PD, and BOP. Future longitudinal studies lasting longer than 
18 months, with a larger number of subject participants, may give evidence and 
demonstrate an even greater negative effect on the periodontium while on AI treatment.  
  
  
  
48 
 
Chapter VI 
Conclusions 
The objective of this investigation was to determine changes in the periodontium 
through the use of clinical parameters, salivary bone biomarkers, and the supplemental 
use of bisphosphonates, vitamin D, and calcium within postmenopausal women with 
breast cancer on aromatase inhibitors. The results from this investigation indicate that 
prolonged use of AI may cause an increase in CAL loss, PD, and BOP.  AI use 
supplemented with bisphosphonates and calcium, may cause an increase in alveolar 
bone loss.   
New guidelines on adjuvant hormonal therapy have been developed by The 
American Society of Clinical Oncology (ASCO) recommending all women diagnosed with 
hormone-receptor-positive breast cancer be offered the option of taking hormonal therapy 
for 10 years.75  Postmenopausal women who  have originally received 5 years of 
tamoxifen, should be offered the choice of continuing tamoxifen for up to 5 more years or 
switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy.75  The 
Knowledge about the prolonged use of AI will lead to an improved risk assessment of oral 
and overall health care of these patients and ultimately may lead to a better standard of 
care for future patients. This study will also provide a basis for further research on the 
oral effects of AI.  
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Figure 1; Images of Gingivitis and Periodontal Disease. 
http://dentistatrajkot.com/Treatments/Gum-Problems/1474 
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Figure 2: Study Subject Participation Consort Chart 
 
 
 
 
 
 
 
 
 
  
142 Subjects assessed for eligibility 
34 excluded; Did not meet inclusion criteria 
45 declined to participate  
       
63 Provided consent  
for full screening 
58 Subjects enrolled in study 
5 withdraws prior to 
Baseline examination 
54 included in analysis 
AI Treatment Group 
n = 29 
6 month 
 n=28 
6 month n=29 
29 Completed Study 25 Completed Study 
12month: n=25 
18 month: n=25 
12 month n=29 
18 month n=29 
1 withdrew after BL visit 
3 withdrew after 6 
month visit 
Control Group  
n = 29 
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Tables 
Table 1. 
Demographic Characteristics of Study Patients on AI and Controls+ 
  
On AI  
N=29 
Control 
N=29   
            
Analysis variable 
Obs % Obs % P 
Value 
Age   61.7 (7.6)   61. 6 (5.4) 0.92 
Ethnicity           
   White 26    89.7 26 89.6   
   Non White 3    10.3 3 10.4 0.92 
Education           
    Less than high school 3    10.5 5 17.8   
    High school diploma 6    20.7 5 17.9   
    More than high school 20    68.8 18 64.3 0.82 
Income           
   No income to $19,999 5 17.9 8 28.6   
   $20,000-$39,999 3 10.7 5 17.9   
   $40,000-$59,999 3 10.7 3 10.7   
   $60,000-$74,999 6 21.4 2  7.1   
   over $75,000 11 39.3 10 35.7 0.22 
Marital Status            
   Married 21 72.4 18 62.1   
   Not Married 8 27.6 11 37.9 0.36 
Has Dental Insurance           
   Yes 21 72.4 23 79.3   
    No 8 27.6 6 20.7 0.76 
Last Dental visit           
   Within last 6 months 25 89.3 27 93.1   
   More than  6 months 3 10.6 2 6.90 0.67 
Smoking Status           
   Current 1   3.4 1  3.4   
    Past 16 55.0 10 34.4   
    Never 12 41.6 18 62.2 0.11 
Bisphosphonate Use           
    Yes 11 37.9 5 17.2   
    No 18 62.1 24 82.8  0.07 
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Calcium Supplement           
    Yes 20 71.4 11 45.8   
    No 8 28.6 13 54.2 0.42 
Vitamin D  Supplement           
    Yes 19 65.5 15 51.7   
    No 10 34.5 13 44.8 0.52 
+Descriptive statistics 
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Table 2.                                                                                                                     
Descriptive Summary of Mean Alveolar Bone Height Among AI users and controls 
at Baseline,12, and 18 months+ 
Time of Measurement On AI 
Mean (SD) 
(N=24)*  
Control 
Mean (SD) 
(N=29) 
t(df) p value 
Mean bone height Baseline* 2.67(.63) 2.68(.45) -0.09(51) 0.92 
Mean bone height 12 months* 2.73(.52) 2.85(.55) -0.75(50) 0.46 
Mean bone height 18 months* 2.86(.55) 2.94(.49) -.50(48) 0.61 
Mean difference in average 
bone height from baseline to 
18 months* 
0.32 (.36) 0.25(.22) 0.80(48) 0.42 
*Maximum sample size across measures. Sample sizes vary slightly from measure to measure. Counts and percentages shown are 
calculated among non-missing.  N= 23  at 12months, N= 21 at 18 months for those on AI.                                                                                                                                                         
+Descriptive statistics, Independent samples-t test 
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Table 3.                                                                                                                           
Descriptive Summary of Mean Difference in Alveolar Bone Height Among AI users 
at Baseline,12, and 18 months+   
Time of 
Measurement 
Mean(SD) 
(N=24)+ 
t(df) p value 
Baseline-
12months 
0.115(0.360) 1.536(22) 0.139 
Baseline-18 
months 
0.327 4.081(20) 0.001 
12-18 months 0.198(0.260) 3.504(20) 0.002 
+Paired t test.              
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure.  N= 23  at 12months, N= 21 at 18 
months. 
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Table 4.                                                                                                                                                  
Descriptive Summary of Mean Difference in Alveolar Bone Height Among 
Controls at Baseline,12, and 18 months+ 
Time of 
Measurement 
Mean(SD) 
(N=29) 
t(df) p value 
Baseline-
12months 
0.169(0.233) 3.892(28) 0.001 
Baseline-18 
months 
0.259(0.228) 6.105(28) 0.000 
12-18 months 0.090(0.217) 2.230(28) 0.034 
+Paired t test 
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Table 5. 
Mean Clinical Attachment Level Among AI Users and Controls at Baseline, 6, 
12,and 18 months* 
Time of 
Measurement 
On AI    Mean 
(SD) (N=29)+  
Control    
Mean (SD) 
(N=29) 
t(df) p value 
Baseline Mean 
CAL 
1.51(.75)   1.42(.39) 0.58(56) .56 
6 month Mean 
CAL 
1.73(.74) 
 
1.24(.29) 3.23(54) 0.001 
12 month Mean 
CAL 
1.72(.36) 
 
1.40(.29) 3.43(50) 0.001 
18 month Mean 
CAL 
1.84(.40) 1.45(.20) 4.53(50) 0.001 
Mean difference 
in CAL from 
baseline to 18 
months 
0.46(.38) 0.03(.33) -4.31(50) 0.001 
+Descriptive statistics, independent sample T Test                                                                                                                       
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure.  N=29 at baseline, 27 at 6 months, 
N=23 at 12,18 months for those on AI 
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Table 6.                                                                                                                                    
Mean Difference in Clinical Attachment Level Among AI Users at Baseline, 6, 
12,and 18 months+ 
Time of 
Measurement 
Mean(SD) 
(N=29)+ 
t(df) p value 
Baseline-
6months 
0.201(0.349) 2.990(26) 0.006 
Baseline-12 
months 
0.335(0.358) 4.489(22) 0.000 
Baseline-18 
months 
0.457(0.384) 5.705(22) 0.000 
+Paired t test                                                                                                                                          
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure. N=29 at baseline, N=23 at 12,18 
months. 
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Table 7.                                                                                                                                  
Mean Difference in Clinical Attachment Level Among Controls at Baseline, 6, 
12,and 18 months+ 
Time of 
Measurement 
Mean(SD) 
(N=29) 
t(df) p value 
Baseline-
6months 
0.177(0.362) 2.627(28) 0.014 
Baseline-12 
months 
0.015(0.357) 0.225(28) 0.823 
Baseline-18 
months 
0.032(0.326) 0.531(28) 0.600 
+Paired t test 
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Table 8. 
Mean Probing Depths Among AI Users and Controls at Baseline, 6, 12, and 18 
Months* 
Time of 
Measurement 
On AI    Mean 
(SD) (N=29)+ 
Control    
Mean (SD) 
(N=29) 
t(df) P value 
Baseline Mean 
PD 
2.00(.27) 
 
 2.00(.29) 
 
0.05(56) 0.96 
6 month Mean 
PD 
2.09(.31) 
 
 
1.76(.24) 
 
4.49(54) 0.001 
12 month Mean 
PD 
2.16(.29) 
 
 
1.95(.20) 
 
 
3.10(50) 0.001 
18 month Mean 
PD 
2.26(.30) 
 
 
2.00(.19) 
 
 
3.72(50) 0.001 
Mean difference 
in PD from 
baseline to 18 
months 
0.28(.28) 0.01(.22) -3.96(50) 0.001 
+Descriptive statistics, independent sample T Test                                                                                                                                                                                                                                                                                                         
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure. N=29 at baseline, N= 27 at 6 
months, N=23 at 12,18 months. 
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Table 9.                                                                                                                                 
Mean Difference in Probing Depths Among AI Users at Baseline, 6, 12, and 18 
Months* 
Time of 
Measurement 
Mean(SD) 
(N=29)+ 
t(df) p value 
Baseline-
6months 
0.093(0.262) 1.856(26) 0.075 
Baseline-12 
months 
0.186(0.266) 3.355(22) 0.003 
Baseline-18 
months 
0.284(0.286) 4.756(22) 0.000 
+Paired t test                                                                                                                                                                                                                                                                                                                           
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure. N=29 at baseline, N= 27 at 6 
months, N=23 at 12,18 months..  
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Table 10.                                                                                                                                         
Mean Difference in Probing Depths Among Controls at Baseline, 6, 12, and 18 
Months* 
Time of 
Measurement 
Mean(SD) 
(N=29) 
t(df) p value 
Baseline-
6months 
0.234(0.260) 4.952(28) 0.000 
Baseline-12 
months 
0.050(0.226) 1.197(28) 0.242 
Baseline-18 
months 
0.245(0.186) 7.097(28) 0.878 
+Paired t test 
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Table 11.                                                                                                                                        
Mean BOP for those on AI and Controls at Baseline, 6, 12, and 18 Months* 
Time of 
Measurement 
 
On AI 
 Mean (SD) 
 (n=29)+ 
Control 
 Mean (SD) 
 (n=29) 
t(df) Pvalue 
Baseline Mean 
BOP 
0.176(.141) 0.107(.080) 2.288(44.250) 0.027 
6 month Mean 
BOP 
0.191(.139) 0.175(.155) 0.420(53.920) 0.676 
12 month 
Mean BOP 
0.267(.147) 0.166(.022) 2.734(50) 0.009 
18 month 
Mean BOP 
0.198(.121) 0.254(.169) 1.393(49.589) 0.170 
Mean 
Difference in 
Average BOP 
from Baseline 
to 18 months 
0.002(0.180) 0.148(0.132) 3.247(39.237) 0.002 
+Descriptive statistics, independent sample T Test                                   
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure. N=29 at baseline, N= 27 at 6 
months, N=23 at 12, 18 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
64 
 
Table 12.                                                                                                                                   
Mean Difference in Bleeding on Probing Among AI Users at Baseline, 6, 12, and 
18 Months+ 
Time of 
Measurement 
Mean(SD) 
(N=29)+ 
t(df) p value 
Baseline-
6months 
0.010(0.153) 0.342(26) 0.735 
Baseline-12 
months 
0.071(0.145) 2.351(22) 0.028 
Baseline-18 
months 
0.002(0.180) 0.053(22) 0.958 
+Paired t test                               
+ Maximum sample size across measures. Sample sizes vary slightly from measure to measure. N=29 at baseline, N= 27 at 6 
months, N=23 at 12, 18 months. 
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Table 13.                                                                                                                                   
Mean Difference in Bleeding on Probing Among Controls at Baseline, 6, 12, and 
18 Months+ 
Time of 
Measurement 
Mean(SD) 
(N=29) 
t(df) p value 
Baseline-
6months 
0.068(0.140) 2.617(28) 0.014 
Baseline-12 
months 
0.059(0.101) 3.171(28) 0.004 
Baseline-18 
months 
0.148(0.132) 6.008(28) 0.000 
+Paired t test 
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Table 14. 
Effect of Vitamin D Use on Bone Height Among AI Users at Baseline, 12, and 18 
Months+ 
Time of Measurement On vit D 
Mean (SD) 
(N=16)* 
not on vit D 
Mean (SD) 
(N=8)+ 
t(df) P 
value 
Mean bone height Baseline 2.52(.58) 2.85(.68) -1.11(17) 0.28 
Mean bone height 12 months 2.63(.44) 2.67(.61) -0.17(16) 0.86 
Mean bone height 18 months 2.84(.50) 2.90(.78) -0.19(16) 0.85 
Mean difference in bone 
height from baseline to 18 
months 
0.31(.32) 0.19(.45) 0.65(16) 0.52 
+Descriptive statistics, independent sample T Test 
*N=14 at 18 months for AI users on vit D 
+N=7 at 18 months for AI users not on vit D 
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Table 15. 
Effect of Vitamin D Use on Bone Height Among Controls at Baseline, 12, and 18 
Months+ 
Time of Measurement On vit D 
Mean (SD) 
(N=15) 
not on vit D 
Mean (SD) 
(N=13) 
t(df) P value 
Mean bone height Baseline 2.79(.480) 2.55(.43) 1.33(26) 0.20 
Mean bone height 12 months 2.97(.639) 2.69(.44) 1.31(26) 0.20 
Mean bone height 18 months 3.03(.543) 2.84(.45) 1.01(26) 0.32 
Mean difference in bone 
height from baseline to 18 
months 
0.24(.20) 0.28(.26) -0.43(26) 0.67 
+Descriptive statistics, independent sample T Test.  1 missing 
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Table 16. 
Effect of Calcium Use on Bone Height Among AI Users at Baseline, 12, and 18 
Months+ 
Time of Measurement On calcium 
Mean (SD) 
(N=17)* 
Not on 
calcium 
Mean (SD) 
(N=7)+ 
t(df) P 
value 
Mean bone height Baseline 2.45(.58) 3.18(.37) -2.56(17) 0.02 
Mean bone height 12 months 2.51(.46) 3.11(.26) -2.44(16) 0.03 
Mean bone height 18 months 2.71(.54) 3.36(.50) -2.13(16) 0.05 
Mean difference in bone 
height from baseline to 18 
months  
0.26(.34) 0.31(.47) -0.27(16) 0.78 
*N=16 at 18 months for AI users on calcium 
+N=6 at 12months, N= 5 for AI users not on calcium  
+Descriptive statistics, independent sample T Test 
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Table 17. 
Effect of Calcium Use on Bone Height Among Controls at Baseline, 12, and 18 
Months+ 
Time of Measurement On calcium 
Mean (SD) 
(N=11) 
Not on 
calcium 
Mean (SD) 
(N=13) 
t(df) P 
value 
Mean bone height Baseline 2.70(.55) 2.72(.41) -0.09(22) 0.92 
Mean bone height 12 
months 
2.91(.72) 2.89(.46) 0.10(22) 0.92 
Mean bone height 18 
months 
2.91(.57) 3.01(.50) -0.42(22) 0.67 
Mean difference in bone 
height from baseline to 18 
months 
0.21(.12) 0.28(.20) -1.04(22) 0.31 
+Descriptive statistics, independent sample T Test 
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Table 18. 
Effect of Bisphosphonate Use on Bone Height Among AI Users at Baseline, 12, 
and 18 Months+ 
Time of Measurement On 
bisphosphonate 
Mean (SD) 
(N=10)* 
 Not on 
bisphosphonate 
Mean (SD) 
(N=14) # 
t(df) P 
value 
Mean bone height 
Baseline 
2.82(.33) 2.51(.76) 1.05(17) 0.31 
Mean bone height 12 
months 
2.73(.40) 2.58(.56) 0.64(16) 0.53 
Mean bone height 18 
months 
2.91(.25) 2.81(.77) .32(16) 0.75 
Mean difference in bone 
height from baseline to 
18 months 
0.08(.27) 0.42(.37) -2.12(16) 0.05 
*N=9 at 18 months for AI users on bisphosphonates 
#N=13 at 12 and 18 months for AI users not on bisphosphonates 
+Descriptive statistics, independent sample T Test 
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Table 19. 
Effect of Bisphosphonate Use on Bone Height Among Controls at Baseline, 12, 
and 18 Months+ 
Time of Measurement On 
bisphosphonates 
Mean (SD) (N=5) 
Not on 
bisphosphonates 
Mean (SD) (N=24) 
t(df) P 
value 
Mean bone height 
Baseline 
2.79(.38) 2.66(.47) 0.60(27) 0.56 
Mean bone height 12 
months 
3.00(.65) 2.82(.54) 0.64(27) 0.52 
Mean bone height 18 
months 
3.00(.37) 2.93(.52) 0.28(27) 0.78 
Mean difference in 
bone height from 
baseline to 18 months 
0.20(.14) 0.27(.24) -0.59(27) 0.56 
+Descriptive statistics, independent sample T Test 
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Table 20.                                                                                                                      
Estimates of Fixed Effectsa 
Variable Estimate Std. Error Sig. 
Intercept 2.42 0.17 <.001 
Baseline Ref Ref Ref 
12 Months 0.13 0.04 0.001 
18 Months 0.27 0.04 <.001 
No Vitamin D at Baseline -0.15 0.17 0.37 
Vitamin D At Baseline Ref Ref Ref 
No Calcium at Baseline 0.81 0.27 0.005 
Calcium at Baseline Ref Ref Ref 
No Bisphosphonate Use at 
Baseline 0.04 0.17 0.81 
Bisphosphonate Use at Baseline Ref Ref Ref 
Not on AI 0.27 0.20 0.19 
On AI Ref Ref Ref 
Not on Calcium and Not on 
Baseline Interaction -0.70 0.34 0.04 
a Dependent Variable: Average Bone Height 
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Table 21.                                                                                                                                                                          
Estimates of Covariance Parametersa 
Covariance Parameters Estimate Std. Error 
 
 
Residual 0.03 0.005  
Intercept 0.24 0.060  
a Dependent Variable: Average Bone Height 
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Table 22.                                                                                                                                                                                  
Pairwise Comparisons for Calcium Use within AI Statusa 
Pairwise Comparisons: Calcium Mean  Std. Error Sig.   
On AI: Yes Calcium 2.50 0.13 0.005  On AI: No Calcium 3.32 0.23  
Not on AI: Yes Calcium 2.78 0.18 0.648  Not on AI: No Calcium 2.89 0.15  
a Dependent Variable: Average Bone Height 
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Table 23.                                                                                                               
Estimatesa 
Estimated Means for Time Mean Std. Error     
Baseline 2.73 0.09   
Wave 2: 12 Months 2.87 0.09   
Wave 3: 18 Months 3.01 0.09   
a Dependent Variable: Average Bone Height 
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Table 24.                                                                                                    
Pairwise Comparisonsa 
Pairwise Comparisons: Time Mean Difference 
Std. 
Error Sig. 
Baseline 
12 
Months -0.13
* 0.04 .003 
18 
Months -0.27
* 0.04 <.001 
12 Months 18 Months -0.13
* 0.04 .003 
a Dependent Variable: Average Bone Height 
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Table 25.                                                                                                                                                           
Osteocalcin Level at Baseline, 12 Months, and 18 Months for Those on AI and 
Controls+ 
Time of Measurement On AI 
Mean (SD) 
(N=28) 
Control 
Mean (SD) 
(N=28) 
t(df) P 
value 
Osteocalcin at  
Baseline* 
182.30(287.17) 150.16(455.46) -0.31(54) 0.75 
Osteocalcin at 12 
months* 
278.11(349.80) 463.50(513.80) 1.36(44) 0.18 
Osteocalcin at 18 
months* 
262.26(534.61) 184.39(388.67) -0.57(45) 0.57 
*Maximum sample size across measures. Sample sizes vary slightly from measure to measure. Counts 
and percentages shown are calculated among non-missing. At 12 months on AI n=19, control n=27. At 18 
months on AI n=18, control n=29.                                                                                                                                              
+Independent sample t test 
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Table 26. 
Correlation of Osteocalcin on Bone Height Among Those on AI at Baseline, 12 
Months, and 18 Months+   
Time of Measurement Bone Height r(Sig) 
Osteocalcin at  Baseline 0.28(.19) 
Osteocalcin at 12 months 0.16(.50) 
Osteocalcin at 18 months 0.22(.37) 
+Pearson Correlation 
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Table 27. 
Correlation of Osteocalcin on Bone Height Among Controls at Baseline, 12 
Months, and 18 Months+  
Time of Measurement Bone Height 
r(Sig) 
Osteocalcin at  Baseline -0.21(.27) 
Osteocalcin at 12 months 0.09(.63) 
Osteocalcin at 18 months 0.14(.46) 
+Pearson Correlation 
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Appendix C  
 
Patient Screening Date:   
 (MON  /  DD  /  YY) 
 
Patient Screening Date:   
 (MON  /  DD  /  YY) 
 
Inclusion Criteria: Yes No 
1. Is the patient postmenopausal as defined by NCCN?    
 a. Prior bilateral oophorectomy or: 
 b. Age > 60 years or: 
 c. Age < 60 and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, 
toremifene or ovarian suppression with FSH and estradiol in the PM range 
 
2. Does the patient have a diagnosis of ER+ breast cancer? 
  
 
 
 
3.    If patient had ER + breast cancer, has the patient been using an AI  
  
 (such as Arimidex, Aromasin or Femara) for less than 1 year?   
 
 
4. Does the patient have 15 teeth? 
  
 
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Oral Health and OHQoL in Early Stage Breast Cancer Survivors: The Role of AIs
University of Michigan
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Exclusion Criteria: 
1. Has the patient received a diagnosis of metastatic breast cancer? 
  
  
 
2. Has the patient received a diagnosis of any type of cancer other than  
   
 early stage breast cancer (Not incl history of thyroid or skin cancer)? 
 
3. Has the patient been told they need antibiotics prior to dental treatment?   
   
 
4. Has the patient received long term use of medications known to    
 affect periodontal status such as immunosuppresives?  
 
5. If the patient has diabetes, do they have a Hemoglobin AC1   
 level of >7.2%?  
 
6. Does the patient have any disease of the immune system or any    
 medical conditions that may influence the outcome of the study 
 (neurologic, psychiatric disorders, systemic infections)? 
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General Information 
Date of Birth 
MON/DD/YY 
            /          /   
 
1. Does the patient use tobacco products? Yes No 
 If yes, circle the products used: 
 cigarettes cigars chewing tobacco other 
 
 If yes:  Quantity per day? _________________ 
 
2. Has the patient used tobacco products in the past? Yes No 
 If yes: Start Year:   Quit Year:   Quantity per day:   
 
 Yes No 
3. Does the patient take bisphosphonates?    
 
Start date:   Stop date:   
Drugs used:   
 
 
Gender 
M          F 
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
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University of Michigan
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Informed Consent Form (ICF) Signed?  Yes  No     
  
ICF Completion Documented?  Yes  No    
               
Medical/Oral History 
Were there any changes to the med/oral history?  Yes  No       
If yes, comment below. 
 
 
Quality of Life 
Was quality of life assessment completed?  Yes  No             
 
Oral Exam 
Was an oral exam performed?   Yes  No     
ADVERSE EVENTS 
Have there been any adverse events? (If “Yes” complete AE 
form) 
YES NO 
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
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University of Michigan
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Please indicate any abnormalities below.  
 
          
Caries Assessment 
Were obvious caries noted?    Yes  No     
If so, please indicate tooth number(s) below. 
 
 
Radiography 
Were standardized radiographs taken?  Yes  No     
 Areas 1    Areas 2   
 
Clinical Periodontal Measures 
Were clinical measures taken?  Yes  No     
 
Oral fluid sampling 
Was saliva collected?  Yes  No    
           
Volume saliva collected? _________ ml (max. 2.0ml) collected in _______ Mts. (max. 15 
Mts.) 
Comments: 
  
  
  
  
 
Examiner Signature:     
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UPPER RIGHT 
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
FGM                         
PD                         
CAL                         
BOP                         
Supragingival 
Plaque 
                        
Supragingival 
Calculus 
                        
Exudate                         
(Y = 1 / N = 0)   1    2    3    4    5    6    7    8  
FGM                         
PD                         
CAL                         
BOP                         
Supragingival 
Plaque 
                        
Supragingival 
Calculus 
                        
Exudate                         
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
Oral Health and OHQoL in Early Stage Breast Cancer Survivors: The Role of AIs 
University of Michigan 
Date 
(MM / DD / YY) 
Patient Number Patient Initials 
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UPPER LEFT 
 m  b  d  m  b  d  m  b  d  m  b  d  m  b  d  m  b  d  m  b  d  m  b  d BUCCAL 
                        FGM 
                        PD 
                        CAL 
                        BOP 
                        Supragingival 
Plaque 
                        Supragingival 
Calculus 
                        Exudate 
  9   10   11   12   13   14   15   16  (Y = 1 / N = 0) 
                        FGM 
                        PD 
                        CAL 
                        BOP 
                        Supragingival 
Plaque 
                        Supragingival 
Calculus 
                        Exudate 
 m  l  d  m  l  d  m  l  d  m  l  d  m  l  d  m  l  d  m  l  d  m  l  d LINGUAL 
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Date 
(MM / DD / YY) 
Patient Number Patient Initials 
  
/                 / 
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Oral Health and OHQoL in Early Stage Breast Cancer Survivors: The Role of AIs 
University of Michigan 
Date 
(MM / DD / YY) 
Patient Number Patient Initials 
  
/                 / 
LOWER LEFT 
 m  b  d  m  b  d  m  b  d  m  b  d  m  b  d  m  b  d  m  b  d  m  b  d BUCCAL 
                        FGM 
                        PD 
                        CAL 
                        BOP 
                        Supragingival 
Plaque 
                        Supragingival 
Calculus 
                        Exudate 
 24   23   22   21   20   19   18   17  (Y = 1 / N = 0) 
                        FGM 
                        PD 
                        CAL 
                        BOP 
                        Supragingival 
Plaque 
                        Supragingival 
Calculus 
                        Exudate 
 m  l  d  m  l  d  m  l  d  m  l  d  m  l  d  m  l  d  m  l  d  m  l  d LINGUAL 
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LOWER RIGHT 
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
FGM                         
PD                         
CAL                         
BOP                         
Supragingival 
Plaque 
                        
Supragingival 
Calculus 
                        
Exudate                         
(Y = 1 / N = 0)  32   31   30   29   28   27   26   25  
FGM                         
PD                         
CAL                         
BOP                         
Supragingival 
Plaque 
                        
Supragingival 
Calculus 
                        
Exudate                         
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
 
 
 
University of Michigan 
Date 
(MM / DD / YY) 
Patient Number Patient Initials 
  
/                 / 
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